A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on B-lymphocyte lineage cells

Pharmaceutical Research

Volumn 27, Issue 3, 2010, Pages 431-441

  Vélez De Mendizábal, Nieves ^a,b   Martínez Forero, Iván ^a,c   Garrido, María J ^c   Bandrés, Eva ^a   García Foncillas, Jesús ^a   Segura, Cristina ^c   Trocóniz, Iñaki F ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

B lymphocytes; Homeostasis; Pharmacokinetic pharmacodynamic model; Topotecan

Indexed keywords

TOPOTECAN;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BERLIN DRUCKSEY IX RAT; BLOOD TOXICITY; CELL LINEAGE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; MALE; NONHUMAN; PHARMACODYNAMICS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; MALE; MODELS, BIOLOGICAL; RATS; TOPOTECAN;

EID: 77949267616     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0025-x     Document Type: Article

References (39)

1. J Crawford DC Dale GH Lyman 2004 Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228 237 10.1002/cncr.11882 14716755 (Pubitemid 38063629)
2. L Sung PC Nathan SM Alibhai GA Tomlinson J Beyene 2007 Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection Ann Intern Med 147 400 411 17876022
3. I Rajman 2008 PK/PD modelling and simulations: utility in drug development Drug Discov Today 13 341 346 10.1016/j.drudis.2008.01.003 18405847 1:CAS:528:DC%2BD1cXkslartL0%3D
4. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 4713 4721 10.1200/JCO.2002.02.140 12488418 (Pubitemid 36025290)
5. LE Friberg MO Karlsson 2003 Mechanistic models for myelosuppression Invest New Drugs 21 183 194 10.1023/A:1023573429626 12889739 1:CAS:528:DC%2BD3sXjtlantrc%3D (Pubitemid 36859318)
6. F Leger WJ Loos R Bugat RH Mathijssen M Goffinet J Verweij A Sparreboom E Chatelut 2004 Mechanism-based models for topotecan-induced neutropenia Clin Pharmacol Ther 76 567 578 10.1016/j.clpt.2004.08.008 15592328 1:CAS:528:DC%2BD2cXhtVKlt7rF (Pubitemid 39601546)
7. JE Latz JJ Rusthoven MO Karlsson A Ghosh RD Johnson 2006 Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy Cancer Chemother Pharmacol 57 427 435 10.1007/s00280-005-0035-2 16322992 (Pubitemid 43087585)
8. IF Troconiz MJ Garrido C Segura JM Cendrós P Principe C Peraire R Obach 2006 Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours Cancer Chemother Pharmacol 57 727 735 10.1007/s00280-005-0112-6 16261364 1:CAS:528:DC%2BD28XjtlWns78%3D
9. GJ Fetterly TH Grasela JW Sherman JL Dul A Grahn D Lecomte J Fiedler-Kelly N Damjanov M Fishman MP Kane EH Rubin AR Tan 2008 Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel Clin Cancer Res 14 5856 5863 10.1158/1078-0432.CCR-08-1046 18794097 1:CAS:528:DC%2BD1cXhtFaitrjN
10. I Ostby G Kvalheim LS Rusten P Grottum 2004 Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: effect of post-transplant G-CSF treatment J Theor Biol 231 69 83 10.1016/j.jtbi.2004.05.010 15363930 1:CAS:528:DC%2BD2cXnsFGgtr4%3D (Pubitemid 39201037)
11. M Scholz C Engel M Loeffler 2006 Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia Br J Haematol 132 723 735 10.1111/j.1365-2141.2005.05957.x 16487172 1:CAS:528:DC%2BD28XjvVWrurY%3D (Pubitemid 43381633)
12. E Gaudin M Rosado F Agenes A McLean AA Freitas 2004 B-cell homeostasis, competition, resources, and positive selection by self-antigens Immunol Rev 197 102 115 10.1111/j.0105-2896.2004.0095.x 14962190 1:CAS:528:DC%2BD2cXhs1Ghsb0%3D (Pubitemid 38142171)
13. S Herzog M Reth H Jumaa 2009 Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling Nat Rev Immunol 9 195 205 10.1038/nri2491 19240758 1:CAS:528:DC%2BD1MXit1yjs7g%3D
14. EJ Kunkel EC Butcher 2003 Plasma-cell homing Nat Rev Immunol 3 822 9 10.1038/nri1203 14523388 1:CAS:528:DC%2BD3sXoslSgsbk%3D
15. N Casares MO Pequignot A Tesniere F Ghiringhelli S Roux N Chaput E Schmitt A Hamai S Hervas-Stubbs M Obeid F Coutant D Metivier E Pichard P Aucouturier G Pierron C Garrido L Zitvogel G Kroemer 2005 Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 1691 1701 10.1084/jem.20050915 16365148 1:CAS:528:DC%2BD2MXhtlCjsrjK (Pubitemid 41815875)
16. L Zitvogel L Apetoh F Ghiringhelli G Kroemer 2008 Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 59 73 10.1038/nri2216 18097448 1:CAS:528:DC%2BD2sXhsVKrsLnP
17. T Takata J Suzumiya T Ishikawa Y Takamatsu H Ikematsu K Tamura 2009 Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP J Clin Exp Hematop 49 9 13 10.3960/jslrt.49.9 19474512
18. C Segura E Bandres IF Troconiz J Garcia-Foncillas O Sayar C Dios-Vieitez MJ Renedo MJ Garrido 2004 Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations Pharm Res 21 567 573 10.1023/B:PHAM.0000022402.00699.5c 15139512 1:CAS:528: DC%2BD2cXjsVWqsLg%3D (Pubitemid 38457278)
19. DL Morrisand WJ Komocsar 1997 Immunophenotyping analysis of peripheral blood, splenic, and thymic lymphocytes in male and female rats J Pharmacol Toxicol Methods 37 37 46 10.1016/S1056-8719(96)00146-3 (Pubitemid 27150644)
20. JM Crawfordand I Goldschneider 1980 THY1 antigen and B lymphocyte differentiation in the rat J Immunol 124 969 976
21. Beal S, Sheiner L, AJ B. NONMEM user's guide. Ellicot: Icon Development Solutions; 2006.
22. TM Ludden SL Beal LB Sheiner 1994 Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection J Pharmacokinet Biopharm 22 431 445 10.1007/BF02353864 7791040 1:STN:280:DyaK2MzhtFWgsg%3D%3D
23. Karlsson M, Holford NH. A tutorial on visual predictive checks, PAGE 17 Abstr 1434 (2008) www.page-meeting.org/?abstract=1434.
24. F Mackay P Schneider 2009 Cracking the BAFF code Nat Rev Immunol 9 491 502 10.1038/nri2572 19521398 1:CAS:528:DC%2BD1MXntFCnsrg%3D
25. F Agenes MM Rosado AA Freitas 1997 Independent homeostatic regulation of B cell compartments Eur J Immunol 27 1801 1807 10.1002/eji.1830270731 9247595 1:CAS:528:DyaK2sXks1CltLc%3D (Pubitemid 27302867)
26. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20 10.1038/sj.clpt.6100241 17571070 1:STN:280:DC%2BD2szlvVakug%3D%3D (Pubitemid 46944205)
27. L Bueno DP de Alwis C Pitou J Yingling M Lahn S Glatt IF Trocóniz 2008 Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice Eur J Cancer 44 142 50 10.1016/j.ejca.2007.10.008 18039567 1:CAS:528: DC%2BD2sXhsVOrurrL (Pubitemid 350256941)
28. S Woo W Krzyzanski WJ Jusko 2008 Pharmacodynamic model for chemotherapy-induced anemia in rats Cancer Chemother Pharmacol 62 123 133 10.1007/s00280-007-0582-9 17891399 1:CAS:528:DC%2BD1cXks1Krsbo%3D (Pubitemid 351537853)
29. JC Panetta P Schaiquevich VM Santana CF Stewart 2008 Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma Clin Cancer Res 14 318 325 10.1158/1078-0432.CCR-07-1243 18172284 1:CAS:528:DC%2BD1cXoslKr
30. MP Cancro 2004 Peripheral B-cell maturation: the intersection of selection and homeostasis Immunol Rev 197 89 101 10.1111/j.0105-2896.2004.0099.x 14962189 1:CAS:528:DC%2BD2cXhs1Ghsbw%3D (Pubitemid 38142170)
31. PM Dammers NK de Boer GJ Deenen P Nieuwenhuis FG Kroese 1999 The origin of marginal zone B cells in the rat Eur J Immunol 29 1522 1531 10.1002/(SICI)1521-4141(199905)29:05<1522::AID-IMMU1522>3.0.CO;2-0 10359106 1:CAS:528:DyaK1MXjtVOktLw%3D (Pubitemid 29224457)
32. Z Yao DC DuBois RR Almon WJ Jusko 2008 Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats J Pharm Sci 97 2820 2832 10.1002/jps.21167 17828751 1:CAS:528:DC%2BD1cXotF2ls74%3D
33. NM Milicevic K Nohroudi Z Milicevic HJ Hedrich J Westermann 2005 T cells are required for the peripheral phase of B-cell maturation Immunology 116 308 317 10.1111/j.1365-2567.2005.02226.x 16236120 1:CAS:528:DC%2BD2MXht1Sitb3O (Pubitemid 41534649)
34. AL Mellor DH Munn 2008 Creating immune privilege: active local suppression that benefits friends, but protects foes Nat Rev Immunol 8 74 80 10.1038/nri2233 18064049 1:CAS:528:DC%2BD2sXhsVKrsLnM
35. W Krzyzanski WJ Jusko 2001 Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition J Pharmacokinet Pharmacodyn 28 57 78 10.1023/A:1011517718990 11253614 1:CAS:528:DC%2BD3MXit1ertr0%3D (Pubitemid 32500081)
36. A Zandvoort ME Lodewijk PA Klok PM Dammers FG Kroese W Timens 2001 Slow recovery of follicular B cells and marginal zone B cells after chemotherapy: implications for humoral immunity Clin Exp Immunol 124 172 179 10.1046/j.1365-2249.2001.01530.x 11422192 1:CAS:528:DC%2BD3MXltFemsbc%3D (Pubitemid 32587600)
37. J Westwemann Z Puskas R Pabbst 1988 Blood transit and recirculation kinetics of lymphocyte subsets in normal rats Scand J Immunol 28 203 210 10.1111/j.1365-3083.1988.tb02432.x (Pubitemid 18216058)
38. CW Tornøe H Agersø T Senderovitz HA Nielsen H Madsen MO Karlsson EN Jonsson 2007 Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues Br J Clin Pharmacol 63 648 64 10.1111/j.1365-2125.2006.02820.x 17096678 1:CAS:528:DC%2BD2sXntl2ku7s%3D (Pubitemid 46753566)
39. RV Overgaard N Holford KA Rytved H Madsen 2007 PKPD model of interleukin-21 effects on thermoregulation in monkeys-application and evaluation of stochastic differential equations Pharm Res 24 298 309 10.1007/s11095-006- 9143-x 17009101 1:CAS:528:DC%2BD2sXjtFCqsg%3D%3D (Pubitemid 46072189)